Prothena Corporation plc (PRTA)
Automate Your Wheel Strategy on PRTA
With Tiblio's Option Bot, you can configure your own wheel strategy including PRTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRTA
- Rev/Share 0.1799
- Book/Share 5.2103
- PB 1.7408
- Debt/Equity 0.0196
- CurrentRatio 7.7172
- ROIC -0.7611
- MktCap 488237937.0
- FreeCF/Share -3.4965
- PFCF -2.594
- PE -2.0003
- Debt/Assets 0.0168
- DivYield 0
- ROE -0.73
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | PRTA | BofA Securities | Neutral | Underperform | -- | $4 | May 28, 2025 |
| Downgrade | PRTA | Cantor Fitzgerald | Overweight | Neutral | -- | -- | May 27, 2025 |
| Downgrade | PRTA | Jefferies | Buy | Hold | -- | $6 | May 27, 2025 |
| Downgrade | PRTA | Oppenheimer | Outperform | Perform | -- | -- | May 27, 2025 |
| Initiation | PRTA | Chardan Capital Markets | -- | Buy | -- | $40 | Dec. 20, 2024 |
News
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.
Read More
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Negative
PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.
Read More
FTRE vs. PRTA: Which Stock Is the Better Value Option?
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
Read More
All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
Prothena (PRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
Published: November 11, 2025 by: Business Wire
Sentiment: Neutral
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation.
Read More
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Read More
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
Read More
Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Read More
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
Read More
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Negative
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
Read More
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
Read More
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Negative
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
Read More
Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Prothena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Chad Swanson - Chief Development Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Participants Emma Seymour - Piper Sandler Jay Olson - Oppenheimer Umer Raffat - Evercore Charles Duncan - Cantor Fitzgerald Jason Butler - Citizens JMP Michael Yee - Jefferies Rudy Li - Chardan Tazeen Ahmad - Bank of America Brian Abrahams - RBC …
Read More
Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm
Published: February 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Read More
About Prothena Corporation plc (PRTA)
- IPO Date 2012-12-18
- Website https://www.prothena.com
- Industry Biotechnology
- CEO Gene G. Kinney
- Employees 163